Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platform:
Izokibep Phase 2b/3 Hidradenitis Suppurativa Data Presented at the 2023 American Academy of Dermatology Annual Meeting
• At 12 weeks, 57% of patients achieved HiSCR75, 38% achieved HiSCR90 and 33% achieved HiSCR100. • Safety results were consistent with previous trials...[read more]
Affibody and Chiesi Group collaborate to develop and commercialize innovative treatments for respiratory diseases
Affibody and Chiesi Group will collaborate closely to develop novel Affibody® molecules as innovative treatments...[read more]
Annual Report 2022
AGM Annual General Meeting 2023
There are currently no posts in the reports and events archive.
Affibody has a broad pipeline with the most advanced projects in clinical studies. The pipeline is designed to demonstrate the value and versatility of the Affibody® technology.
It is the competence and the engagement of all coworkers that make Affibody an inspiring and exciting place to work at. We know we reach much further in innovation, efficiency and quality by having a work place where we as coworkers care for each other, are ambitious and know and value our own contribution to the end result.